Skip to main content
Neuro-Oncology Advances logoLink to Neuro-Oncology Advances
. 2021 Mar 25;3(Suppl 1):i11. doi: 10.1093/noajnl/vdab024.044

DDRE-22. TARGETING SERINE SYNTHESIS IN BRAIN METASTASIS

Bryan Ngo 1, Eugenie Kim 2, Victoria Osorio-Vasquez 2, Sophia Doll 3, Sophia Bustraan 2, Roger Liang 4, Alba Luengo 5, Shawn Davidson 6, Ahmed Ali 5, Gino Ferraro 7, Grant Fischer 8, Ariana Plasger 4, Vinagolu Rajasekhar 1, Edward Kastenhuber 4, Roozbeh Eskandari 1, Sarah Bacha 4, Roshan Sriram 4, Samuel Bakhoum 1, Matija Snuderl 2, Paolo Cotzia 2, John Healey 1, David Sabatini 9, Drew Jones 2, Jean Zhao 10, Min Yu 11, Rakesh Jain 7, Kayvan Keshari 1, Michael Davies 8, Matthew Vander Heiden 5, Eva Hernando 2, Matthias Mann 3, Lewis Cantley 4, Michael Pacold 2
PMCID: PMC7992201

Abstract

The brain environment is low in amino acids, including serine and glycine, both of which are important for tumor growth as they are precursors of proteins and nucleotide bases. How tumor cells overcome these conditions to proliferate and survive in the brain is incompletely understood. Here, we show that 3-phosphoglycerate dehydrogenase (PHGDH), which catalyzes the first and rate-limiting step of glucose-derived serine synthesis, enables brain metastasis in multiple human types and in preclinical models. Genetic suppression and small molecule inhibition of PHGDH attenuated brain metastasis, but not extra cranial tumors, and improved the overall survival of mice bearing brain metastasis. These results demonstrate that the tumor nutrient microenvironment determines tumor cell sensitivity to loss of serine synthesis pathway activity and raise the possibility that serine synthesis inhibitors may be useful in the treatment of brain metastases.


Articles from Neuro-oncology Advances are provided here courtesy of Oxford University Press

RESOURCES